Investor
NEXTBio Capital Management LP
CIK 0002038158 · filed 2026-05-14 · SEC filing
13F book
$215.4M
Positions
24
1 new · 0 sold
Largest name
14.8%
Terns Pharmaceuticals Inc
Est. mark
$24.8M
Price effect on 23 names still held. Flow $20.1M.
| Name | Ticker | Shares | Value | Weight | Est. mark | Change |
|---|---|---|---|---|---|---|
| Terns Pharmaceuticals Inc | — | 604.5K | $31.9M | 14.8% | $6.79M | Added$9.6M |
| Protagonist Therapeutics, Inc | PTGX | 229.6K | $24.2M | 11.2% | $4.15M | Held |
| Shattuck Labs, Inc. | STTK | 3.15M | $20.3M | 9.4% | $8.76M | Held |
| Vor Biopharma Inc. | VOR | 1000K | $17.8M | 8.3% | $4.76M | Held |
| Compass Pathways Plc | CMPS | 2.02M | $11.2M | 5.2% | −$1.03M | Added$5.99M |
| Rhythm Pharmaceuticals, Inc. | RYTM | 126.1K | $11M | 5.1% | −$1.36M | Added$3.73M |
| Xenon Pharmaceuticals Inc. | XENE | 183.2K | $10.7M | 4.9% | $2.44M | Cut$2.42M |
| Palvella Therapeutics Inc Ne | — | 82.7K | $10.3M | 4.8% | $1.65M | Held |
| Zenas BioPharma, Inc. | ZBIO | 426.7K | $8.34M | 3.9% | −$5.4M | Added−$3.35M |
| Inventiva Sa | — | 1.33M | $7.4M | 3.4% | $1.17M | Added$1.36M |
| Verastem, Inc. | VSTM | 1.31M | $6.93M | 3.2% | −$3.16M | Cut−$3.17M |
| Crescent Biopharma, Inc. | CBIO | 372.9K | $6.85M | 3.2% | $2.43M | Held |
| Oric Pharmaceuticals, Inc. | ORIC | 523.6K | $6.63M | 3.1% | $2.35M | Cut$1.6M |
| Structure Therapeutics Inc. | GPCR | 133.2K | $6.42M | 3.0% | −$2.02M | Added−$146.4K |
| Vaxcyte, Inc. | PCVX | 95.2K | $5.53M | 2.6% | $1.14M | Cut$1.13M |
| Cogent Biosciences, Inc. | COGT | 131.2K | $5.05M | 2.3% | $284.6K | Added$1.65M |
| Compass Therapeutics, Inc. | CMPX | 848.2K | $4.49M | 2.1% | −$67.9K | Cut−$1.5M |
| Evommune, Inc. | EVMN | 184.1K | $4.23M | 2.0% | $1.08M | Cut$323.4K |
| Oculis Holding Ag | — | 149.6K | $3.98M | 1.8% | $990.3K | Cut$987.1K |
| Zai Lab Ltd | ZLAB | 183.4K | $3.45M | 1.6% | $191.1K | Added$567.3K |
| Disc Medicine, Inc. | IRON | 52.7K | $3.37M | 1.6% | −$661.8K | Added−$30.2K |
| Kalvista Pharmaceuticals Inc | — | 131.8K | $2.65M | 1.2% | $524.5K | Held |
| Summit Therapeutics Inc. | SMMT | 89.7K | $1.7M | 0.8% | — | New |
| Adicet Bio, Inc. | ACET | 157.8K | $1.07M | 0.5% | −$254.1K | Held |
Positions as of Q1 2026. 13F filings arrive up to 45 days after quarter-end and omit shorts. Values are quarter-end marks, as filed. Estimated mark is the price effect on shares still held — not realized P&L or investment advice.